### Highlights of This Issue 1023

#### SMALL MOLECULE THERAPEUTICS

**1025**  
LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma  
Linlin Yang, Bhavna Kumar, Changxian Shen, Songzhu Zhao, Dukagjin Blakaj, Tianyun Li, Mitchell Romito, Theodoros N. Teknos, and Terence M. Williams

**1036**  
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer  
Shweta Joshi, Alok R. Singh, Kevin X. Liu, Timothy V. Pham, Muamera Zulcic, Dylan Skola, Hyun Bae Chun, Christopher K. Glass, Guillermo A. Morales, Joseph R. Garlich, and Donald L. Durden

**1045**  
Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma  
Yang Yu, Yanling Zhao, Yihui Fan, Zhenghu Chen, Hui Li, Jiaxiong Lu, Kevin Guo, Sarah E. Woodfield, Sanjeev A. Vasudevan, Jianhua Yang, and Jed G. Nuchtern

#### LARGE MOLECULE THERAPEUTICS

**1069**  
A Tumor-Peptide–Based Nanoparticle Vaccine Elicits Efficient Tumor Growth Control in Antitumor Immunotherapy  
Carolin Heße, Sebastian Kollenda, Olga Rotan, Eva Pastille, Alexandra Adamczyk, Christina Wenzek, Wiebke Hansen, Matthias Eppl, Jan Ruer, Astrid M. Westendorf, and Torben Knuschke

---

### CANCER BIOLOGY AND TRANSLATIONAL STUDIES

**1081**  
A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy  
Pottayil G. Sasikumar, Raghuvier K. Ramachandra, Srinivas Adurthi, Amit A. Dhusdashiya, Sureshkumar Vadlamani, Koneswararao Vemula, Sreihribabu Vunnunum, Leena K. Satyam, Dooderi S. Samiulla, Krishnaprasad Subbarao, Rashmi Nair, Rajeev Shrimali, Nagaraj Gowda, and Murali Ramachandra

**1092**  
Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effecter Bispecific Design  
Nam-Kyung Lee, Yang Su, Scott Bidlingmaier, and Bin Liu

**1104**  
Discovery of A Novel EGFR-Targeting Antibody–Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies  
Kaijie He, Jianyan Xu, Jindong Liang, Jiahua Jiang, Mi Tang, Xin Ye, Zhebin Zhang, Lei Zhang, Beibei Fu, Yan Li, Chang Bai, Lianshan Zhang, and Weikang Tao
Table of Contents

1137 Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer
Leslie Duplaquet, Martin Figeac, Frédéric Lepretre, Charline Frandemiche, Céline Villenet, Stéhémazade Sebda, Nasrin Sarafan-Vasseur, Mélanie Bénôzeté, Audrey Vincenot, Gautier Goormachtigh, Laurence Wicquart, Nathalie Rousseau, Ludivine Beaussire, Stéphanie Truant, Pierre Michel, Jean-Christophe Sabourin, Françoise Galateau-Sallé, Marie-Christine Copin, Gérard Zalcman, Yvan De Launoit, Véronique Fafeur, and David Tulasne

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1149 Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis
Filip Janku, Eli L. Diamond, Aaron M. Goodman, Vaijayanthi Kandadai Raghavan, Tamara G. Barnes, Shumei Kato, Omar Abdel-Wahab, Benjamin H. Durham, Funda Meric-Bernstam, and Razelle Kurzrock

1158 Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer
Weiguo Cao, Yaping Xu, Lianpeng Chang, Yuhua Gong, Liren Li, Xianwei Mo, Xin Zhang, Guole Lin, Jialin Zhou, Dan Liu, Yuting Yi, Pingping Dai, Chenchen Zhu, Tao Liu, Yuxing Chu, Yanfang Guan, Yongsheng Chen, Jiayin Wang, Xuefeng Xia, Ling Yang, Xin Yi, and Yong Cheng

MODELS AND TECHNOLOGIES

1168 Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing
Jasmien Cornille, Agnieska Wozniak, Haifu Li, Yannick Wang, Bram Boeckx, Yemarshet K. Gebreyohannes, Jasmien Wellens, Ulla Vanleeuw, Daphne Hompes, Marguerite Stas, Friedel Sinnaeve, Hazem Wafa, Dietmar Lambrechts, Maria Debiec-Rychter, Raf Sciot, and Patrick Schöffski

RETRACTIONS

1179 Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo
Girija Dasmahapatra, Dmitry Lembersky, Minkyeeong P. Son, Elisa Attkisson, Paul Dent, Richard I. Fisher, Jonathan W. Friedberg, and Steven Grant

1180 Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo
Girija Dasmahapatra, Dmitry Lembersky, Minkyeeong P. Son, Hiral Patel, Derick Peterson, Elisa Attkisson, Richard I. Fisher, Jonathan W. Friedberg, Paul Dent, and Steven Grant

1181 Retraction: In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells
Girija Dasmahapatra, Hiral Patel, Johnathan Friedberg, Steven N. Quayle, Simon S. Jones, and Steven Grant

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The BCL-2/Xr pro-survival proteins compromise the effectiveness of cancer therapies. Here, Zoeller and colleagues provide in vivo evidence that neutralization of BCL-2/Xr via navitoclax/ABT-263 enhances the cytotoxic effectiveness of the HER2-targeted antibody-drug conjugate T-DM1. To assess the pathological responses associated with combined treatments, the authors performed specialized histological staining. The cover represents microscopic analysis of a Masson’s trichrome stained patient-derived xenograft treated with T-DM1 and navitoclax/ABT-263, and demonstrates substantial elimination of the tumor cells (red) and the emergence of a reactive stroma (blue). For more information, please see the article starting on page 1115.